Gretchen S. Dieck, PhD
Gretchen S. Dieck, PhD
Dr. Gretchen Dieck joined UBC in 2010 and has more than 25 years of experience in the areas of epidemiology and risk management. As Vice President, Safety, Epidemiology, Registries and Risk Management, Dr. Dieck focuses on the development of KAB protocols and surveys, risk management consulting, epidemiology consulting, and safety related gap analysis. She has worked with one of the most diverse and prolific portfolios of drug development and brings a unique combination of strategic thinking and practical experience to the development and implementation of risk management programs.
Prior to joining UBC, Dr. Dieck was Senior Vice President, Safety and Risk Management at Pfizer Inc. where she began her 23-year tenure with the company in 1986 as a staff epidemiologist. While heading the Safety and Risk Management group, she was responsible for providing risk management support and compliance functions across the product portfolio. Included in these responsibilities were the case processing and risk management functions relating to epidemiology and medical safety evaluation as well as safety and risk management related analysis and documentation. One of her notable accomplishments while at Pfizer was the conceptualization and implementation of Pfizer’s Medicine Safety website.
Dr. Dieck received her M. Phil and PhD from Yale University where she also held a Postdoctoral Fellowship in Epidemiology. She is a member of the American College of Epidemiology, the Society for Epidemiologic Research, the ICH Risk Communication Working Group, the American Public Health Association and a founding member of the International Society for Pharmacoepidemiology. She served as an Assistant Adjunct Professor of Public Health at Columbia University’s School of Public Health. She is past Chair of the Pharmacovigilance and Epidemiology Technical Group of PhRMA and headed the Risk Management Working Group of the Pharmaceuticals Innovation Steering Committee of PhRMA. Dr. Dieck represented PhRMA during PDUFA III and PDUFA IV discussions and co-led the PostMarket Safety Group for PDUFA IV.
Registry: Its Use in Real-World Data Collection, ISPOR, June 2014
Preparing for safety issues following drug approval: pre-approval risk management considerations, Therapeutic Advances in Drug Safety, 2013